A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to allow evaluation of long-term clinical effect and safety
outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended
treatment duration with AP-CD/LD after they have successfully completed the Phase 3 core
study IN 11 004 ('core study', a phase III, multicenter, randomized, double-blind,
double-dummy, active-controlled Phase 3 study to assess the safety and efficacy of AP CD/LD
versus IR CD/LD in fluctuating PD patients).
Phase:
Phase 3
Details
Lead Sponsor:
Intec Pharma Ltd.
Collaborator:
PRA Health Sciences
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa